Edwards Lifesciences Corporation $EW Stock Acquired by TrinityBridge Ltd

TrinityBridge Ltd boosted its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 26,553.7% in the third quarter, HoldingsChannel reports. The firm owned 79,961 shares of the medical research company’s stock after purchasing an additional 79,661 shares during the period. TrinityBridge Ltd’s holdings in Edwards Lifesciences were worth $6,904,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Flagship Harbor Advisors LLC lifted its position in shares of Edwards Lifesciences by 1.2% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 10,615 shares of the medical research company’s stock valued at $916,000 after acquiring an additional 125 shares during the period. Fifth Third Wealth Advisors LLC grew its holdings in Edwards Lifesciences by 1.8% in the third quarter. Fifth Third Wealth Advisors LLC now owns 7,268 shares of the medical research company’s stock worth $627,000 after purchasing an additional 132 shares during the period. Signaturefd LLC grew its holdings in Edwards Lifesciences by 1.4% in the third quarter. Signaturefd LLC now owns 10,034 shares of the medical research company’s stock worth $866,000 after purchasing an additional 142 shares during the period. NorthRock Partners LLC grew its holdings in Edwards Lifesciences by 1.0% in the second quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company’s stock worth $1,465,000 after purchasing an additional 153 shares during the period. Finally, Soltis Investment Advisors LLC increased its stake in Edwards Lifesciences by 2.4% in the third quarter. Soltis Investment Advisors LLC now owns 6,479 shares of the medical research company’s stock valued at $559,000 after purchasing an additional 153 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently weighed in on EW. Deutsche Bank Aktiengesellschaft set a $104.00 price objective on shares of Edwards Lifesciences in a report on Tuesday, October 27th. Barclays upgraded Edwards Lifesciences to a “strong-buy” rating in a research note on Wednesday, October 7th. Jefferies Financial Group raised their target price on Edwards Lifesciences from $102.00 to $105.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Citigroup reaffirmed a “buy” rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research report on Monday, October 5th. Finally, Raymond James Financial upped their price target on Edwards Lifesciences from $100.00 to $103.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $101.88.

Edwards Lifesciences Stock Up 2.2%

Shares of NYSE EW opened at $95.32 on Wednesday. The stock has a market capitalization of $54.88 billion, a P/E ratio of 54.78, a P/E/G ratio of 2.44 and a beta of 0.85. The company has a 50-day moving average price of $88.31 and a 200-day moving average price of $85.53. Edwards Lifesciences Corporation has a 1 year low of $74.66 and a 1 year high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction that occurred on Thursday, October 8th. The stock was sold at an average price of $85.65, for a total transaction of $53,017.35. Following the completion of the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,428,912.10. The trade was a 1.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the sale, the senior vice president directly owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 5,045 shares of company stock worth $451,596 in the last quarter. Insiders own 0.31% of the company’s stock.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: In the PROGRESS trial, TAVR outperformed clinical surveillance on a two-year composite of death or heart-failure events among moderate aortic stenosis patients with at-risk features. The result could support earlier use of TAVR in selected patients. PROGRESS trial results
• Positive Sentiment: The CLASP II TR trial found Edwards’ PASCAL system superior to medical therapy alone at six months, with reduced tricuspid regurgitation and improved health status sustained through one year. This strengthens the clinical case for the company’s tricuspid-repair offering. CLASP II TR trial results
• Positive Sentiment: Bank of America’s analyst view was that PROGRESS supports expanding TAVR to selected moderate aortic stenosis patients, suggesting a potential new use for the procedure. Bank of America analyst view
• Negative Sentiment: RBC said the PROGRESS data are unlikely to meaningfully expand the overall TAVR market, a caveat to expectations that the trial will translate into broad commercial growth. RBC assessment of PROGRESS

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.